Cargando…

Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates

Non-alcoholic fatty liver disease (NAFLD), or metabolic (dysfunction)-associated fatty liver disease (MAFLD), is characterized by high global incidence and prevalence, a tight association with common metabolic comorbidities, and a substantial risk of progression and associated mortality. Despite the...

Descripción completa

Detalles Bibliográficos
Autores principales: Prikhodko, Veronika A., Bezborodkina, Natalia N., Okovityi, Sergey V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869100/
https://www.ncbi.nlm.nih.gov/pubmed/35203484
http://dx.doi.org/10.3390/biomedicines10020274
_version_ 1784656417588772864
author Prikhodko, Veronika A.
Bezborodkina, Natalia N.
Okovityi, Sergey V.
author_facet Prikhodko, Veronika A.
Bezborodkina, Natalia N.
Okovityi, Sergey V.
author_sort Prikhodko, Veronika A.
collection PubMed
description Non-alcoholic fatty liver disease (NAFLD), or metabolic (dysfunction)-associated fatty liver disease (MAFLD), is characterized by high global incidence and prevalence, a tight association with common metabolic comorbidities, and a substantial risk of progression and associated mortality. Despite the increasingly high medical and socioeconomic burden of NAFLD, the lack of approved pharmacotherapy regimens remains an unsolved issue. In this paper, we aimed to provide an update on the rapidly changing therapeutic landscape and highlight the major novel approaches to the treatment of this disease. In addition to describing the biomolecules and pathways identified as upcoming pharmacological targets for NAFLD, we reviewed the current status of drug discovery and development pipeline with a special focus on recent evidence from clinical trials.
format Online
Article
Text
id pubmed-8869100
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88691002022-02-25 Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates Prikhodko, Veronika A. Bezborodkina, Natalia N. Okovityi, Sergey V. Biomedicines Review Non-alcoholic fatty liver disease (NAFLD), or metabolic (dysfunction)-associated fatty liver disease (MAFLD), is characterized by high global incidence and prevalence, a tight association with common metabolic comorbidities, and a substantial risk of progression and associated mortality. Despite the increasingly high medical and socioeconomic burden of NAFLD, the lack of approved pharmacotherapy regimens remains an unsolved issue. In this paper, we aimed to provide an update on the rapidly changing therapeutic landscape and highlight the major novel approaches to the treatment of this disease. In addition to describing the biomolecules and pathways identified as upcoming pharmacological targets for NAFLD, we reviewed the current status of drug discovery and development pipeline with a special focus on recent evidence from clinical trials. MDPI 2022-01-26 /pmc/articles/PMC8869100/ /pubmed/35203484 http://dx.doi.org/10.3390/biomedicines10020274 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Prikhodko, Veronika A.
Bezborodkina, Natalia N.
Okovityi, Sergey V.
Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates
title Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates
title_full Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates
title_fullStr Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates
title_full_unstemmed Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates
title_short Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates
title_sort pharmacotherapy for non-alcoholic fatty liver disease: emerging targets and drug candidates
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869100/
https://www.ncbi.nlm.nih.gov/pubmed/35203484
http://dx.doi.org/10.3390/biomedicines10020274
work_keys_str_mv AT prikhodkoveronikaa pharmacotherapyfornonalcoholicfattyliverdiseaseemergingtargetsanddrugcandidates
AT bezborodkinanatalian pharmacotherapyfornonalcoholicfattyliverdiseaseemergingtargetsanddrugcandidates
AT okovityisergeyv pharmacotherapyfornonalcoholicfattyliverdiseaseemergingtargetsanddrugcandidates